|D008173||Lung Diseases, Obstructive NIH||0.45|
|D008171||Lung Diseases, NIH||0.41|
|D011024||Pneumonia, Viral NIH||0.14|
|D045169||Severe Acute Respiratory Syndrome NIH||0.06|
|D018352||Coronavirus Infections NIH||0.05|
There is one clinical trial.
Molecular testing (e.g PCR) of respiratory tract samples is the recommended method for the identification and laboratory confirmation of COVID-19 cases. Recent evidence reported that the diagnostic accuracy of many of the available RT-PCR tests for detecting SARS-CoV2 may be lower than optimal. Of course, the economical and clinical implications of diagnostic errors are of foremost significance and in case of infectious outbreaks, namely pandemics, the repercussions are amplified. False positives and false-negative results may jeopardize the health of a single patient and may affect the efficacy of containment of the outbreak and of public health policies. In particular, false-negative results contribute to the ongoing of the infection causing further spread of the virus within the community, masking also other potentially infected people.
Description: assess if inpatients who presented with pneumonia but had a negative test for Covid-19 are positive at the serology for SARS-CoV-2.Measure: Serology Time: 3 weeks
Description: to find if the combination of CT scan and serology could help us in the identification of those patients who were initially negative at laboratory testing alone.Measure: Efficacy of CT scan and Serology Time: 3 weeks
Description: the efficacy of different pharmaceutical treatments against Covid-19Measure: Efficacy of different pharmaceutical treatments Time: 3 weeks